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A B S T R A CT  
Pneumonia of unknown etiology was reported from Wuhan, Hubei province of China on 31th December, 
2019. WHO declared the outbreak a public health emergency of international concern on 30th January, 
2020. Thereafter, it has spread throughout China and reached the level of a pandemic expanding to 210 
countries with 9,653,048 confirmed cases and 491,128 deaths as per COVID-19 Situation Report issued 
by WHO based on data received upto 27th June, 2020. Manifold questions remain unanswered regarding 
pathogen associated variables for amplification dynamics, host environment and agent interaction. 
Multidimensional issues regarding the epidemiological spectrum have cropped up but still unresolved. 
This study makes an effort to analyse the information gathered from published articles of renowned 
journals and newsletters to explore the epidemiological characteristics of COVID-19 disease. Hereby, we 
have tried to assemble the questions epidemiological lacunae created by the divergent demographic 
characteristics, long incubation period, secondary attack rate and puzzling transmission dynamics of 
COVID-19 that remain unanswered. 
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1. Introduction 
There is a Greek Myth in which Gods had given Pandora a locked jar and advised never to open. Driven 
by human weakness she nevertheless opened it, releasing the world’s misfortune. Such is the scenario 
with COVID-19 [1]. Pneumonia of unknown etiology was reported from Wuhan, Hubei province of 
China on 31st December, 2019. WHO declared the outbreak a public health emergency of international 
concern on 30th January, 2020 [2]. Thereafter, it has spread throughout China, expanding to 210 
countries and reached the level of a pandemic. On 11th February 2020 a name was announced for this 
novel coronavirus disease: COVID-19 [3]. Contact tracing, testing and treatment supported by social 
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distancing are the gold-standards for harnessing this global pandemic. To this effect, on March 24th, the 
Government of India ordered a nationwide lockdown for 21days at a point when the number of 
confirmed cases was approximately 500 in the country [4]. Currently, India has witnessed cases mostly 
related to travel and local transmission from imported cases. Community transmission has not been 
confirmed yet nationally. However, there is a state-wise difference in opinion regarding the same. 
Historically, if we look back, there were multiple viral pandemics and outbreaks globally. Corona virus 
also established previous pandemics, SARS (2003) and MERS (2012), but SARS-CoV-2 emergence takes 
a different trajectory. Despite the fact that each apparently has an origin in enzootic bat viruses [1], 
multiple questions remain unanswered regarding pathogen associated variables for amplification 
dynamics, host environment, agent interaction. With this present analysis of different documentations, 
we tried to understand the different variables pertaining to the COVID-19 disease transmission 
dynamics. 
2. Objective 
Descriptive analysis of COVID-19 epidemiological characteristics based on different published 
articles. We tried to analyse the information gathered from published articles of renowned journals and 
newsletters to explore the epidemiological characteristics ofCOVID-19 disease.  
3. Discussion 
A pooled analysis of confirmed COVID-19 cases reported in China estimated the median incubation 
period to be 5.1days, similar to SARS. However, the symptoms appeared in 97.5% subjects within 11.5 
days [5]. This infection has led in a multitude of knowledge gaps that has resulted in random spread and 
initiation of a pandemic of global proportion. A brief compilation of the major lacunae perplexing 
researchers worldwide: 
3.1 Transmission dynamics: 
Any infectious disease outbreak can be characterized by its reproductive number Ro. If Ro>1, cases 
are statistically capable of secondary transmission. For COVID-19 outbreak in China, Ro ranged from 2.5-
2.9 [6,7] in contrast to 1918-19 Spanish influenza pandemic that killed 50 million people worldwide with 
estimated Ro being 1.8. For SARS 2003 and MERS 2012 outbreak it was Ro<2 [8]. So, the current pattern 
of COVID-19 presents a concerning possible shorter doubling time of cases. Unlike SARS-2003 and 
MERS-2012 outbreaks where almost all onward transmission occurred after symptom onset, COVID-19 
transmission can occur prior to that. Based on this fact ‘contacts’ have been defined as “those who have 
been in close contact since 2 days before onset of symptoms of suspected and confirmed cases, or 2 days 
prior to asymptomatic cases”. This reflects that secondary transmission of COVID-19 virus is possible 
minimum 2 days prior to symptom onset [9]. Studies have also shown evidences of transmission by 
asymptomatic subjects who were later tested positive for SARS-CoV-2. This is an indication to the latent 
period extending from the point of infection to the onset of infectiousness which is shorter than the 
incubation period [10, 11]. The complete severe acute respiratory syndrome of COVID-19 is shown by 
only 5-10% of the total infected persons [12]. Whilst respiratory droplets and fomites have been advocated 
to be the major modes of transmission, studies have shown airborne transmission might be the cause of 
the extraordinary attack rate [13, 14]. Apart from oral swabs and bronchoalveolar lavage fluid (BALF) the 
virus has also been detected in anal swabs and blood [15, 16]. This con not be the possibility of viral 
shedding through feco-oral and body-fluid routes providing a lead for further interventions. Even though 
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the human coronavirus does not replicate outside the living cell, it remains viable on contaminated 
surfaces for varied durations, subject to humidity and temperature [17, 18]. A high stability was found at 
4°C in-vitro but when temperature raised to 70°C, the inactivation time reduced to 5 min [19, 20]. Hence, 
delving into new factors and new temperature determinants can put light on the combination effect of 
temperature and humidity on the half-life of the virus. Droplet inoculation on different surfaces showed 
that the virus did not persist post 3 hour incubation on printing/tissue papers and 2 day incubation on 
wood. The viability was higher on smooth surfaces and recovery ceased on day-4 from glass and bank 
notes and day-7 on stainless steel and plastic. Persistence was observed on the outer layer of surgical mask 
even on day-7 [1]. Hence, the survival of the virus varies on different surfaces and gives an idea towards 
the safety and utility guidelines that can prove vital in breaking the transmission chain via inanimate 
objects in community setting. 
3.2 Morbidity and mortality 
  Mean duration of onset of symptoms to death was found to be 17.8 days (95% CI 16.9-19.2) and to 
hospital discharge 24.7days (CI 22.9-28) [20]. Estimated fatality may vary between countries owing to 
difference in prevention, control and implemented policy utilization. Severity of a disease is usually 
measured by the fatality ratio that is the reported Case Fatality Ratio (CFR). Verity R. et al reported from a 
model based analysis, accounting for censoring and ascertainment bias, crude case fatality ratio of 3.67%. 
Best estimate from China reported, after adjustment of demography and ascertainment of CFR, to be 
1.38% [20]. Even if the CFR of COVID-19 is lower as compared to 14–15% for SARS outbreak [21] and 
approximately 35% for MERS outbreak [22], rapid progression and evidences of multiple human-to-
human transmission modes suggest SARS-CoV-2 to be more dangerous [23-26]. A preliminary study 
conducted in the Hubei province found that almost a four-fifth of the affected population were aged 30-
69 years, indicating a major impact on the global workforce. The age group ≥80 have the highest case 
fatality ratio [27]. A new question is cropping up regarding role of ethnicity in incidence or outcome of 
COVID-19 [28]. A higher incidence and severity observed among ethnic minorities and first 10 doctors in 
the UK to succumb to COVID-19 identified to be from the ethnic section [29]. This could be due to 
socio-cultural, lifestyle, genetic predisposition and pathophysiological differences in susceptibility to 
infection. A higher mortality is observed in presence of co-morbidities [26] and hence, ethnic groups with 
higher rates of diabetes, hypertension and other co-existing conditions are at exemplified risk [28, 30-32] 
countries like India with a diverse geographic and demographic spectrum calls for further detailed studies. 
Even though data suggests no significant gender disproportion with 56% males being affected [30] but a 
higher COVID-19 related mortality among males may be the result of immunological or habitual 
differences such as smoking [33,34]. However it is too early to make any assumptions. Children of all age 
groups are sensitive to COVID-19 with neonates being the most vulnerable [35]. Disease severity and case 
fatality ratio is less as compared to adults [36, 37]. This is puzzling as children are often considered at 
higher risk of viral respiratory diseases owing to limited immune experience and incomplete airway 
development [38]. It indicates a knowledge gap that must be filled fast as children can be important 
transmission facilitators for COVID-19. As for pregnancy, no obstetric or neonatal complications related 
to COVID-19 have been reported so far [39]. But data being insufficient, the medical and social risk 
cannot be ruled out. Very recently a non-peer-reviewed article by Miller A. reported a correlation between 
universal BCG vaccination and reduced impact of COVID-19. Five countries without universal BCG 
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vaccination policy had 264.90±134.88 cases per million and 55 countries having a current policy had 
59.54±23.29 cases per million inhabitants. A plausible explanation may be the broad spectrum protection 
against viral infection and sepsis conferred by BCG vaccine [40]. But this report was refuted as an 
ecological fallacy [41]. Reports of countries with high burden of leprosy being less vulnerable are also 
present [42]. Nevertheless this does not rule out the possibility of a higher proportion of asymptomatic 
cases in comparison to clinical cases. 
3.3 Diagnostics 
The detection of SARS-CoV-2 is conducted by real-time RT-PCR method and screened via 
serological tests. Although former is confirmatory, it can only detect the virus during acute stage of viral 
shedding which is uncertain in case of COVID-19, plus the sensitivity and specificity of the COVID-19 
real-time RT-PCR test is not 100% [43]. The serocon version kinetics shows a gap between end of 
convalescent phase and period of antibody response. Therefore, the conversion of a potential carrier of 
SARS-CoV-2 to seronegative state is one of significance in preventing/controlling community 
transmission. This might give serological testing an upper hand with respect to public health in the 
detection of asymptomatic/subclinical cases [44]. Thus, from different report analysis, a four months old 
disease appeared with total puzzling epidemiological characteristics, initiating a global pandemic. 
Multidimensional issues regarding the epidemiological spectrum came forward but could not be resolved. 
Animal-to-human viral transmission is yet to be confirmed by global medical fraternity as differences of 
opinion are cropping [45]. Regarding ethnicity, reports from developed countries are having perplexing 
implications. The reason isn’t clear as to why minority origin countries are reporting lesser case incidences 
and symptomatic patients. Clinical manifestation is in line with airborne respiratory infections but 
gastrointestinal complications are now emerging [33]. The global diversity in mortality rates with highest 
being reported from developed countries is difficult to reason. Regarding diagnosis and treatment, the 
prevailing dilemma regarding the most suitable test is unresolved and preference of hydroxychloroquine 
by administrators without solid evidence with none other proper antiviral drug in pipeline except 
convalescent plasma showing some hope is perturbing. 
4. Conclusion 
Above analysis brings into fore the puzzling epidemiological characteristics of COVID-19 pandemic 
including identification of animal reservoir, determination of infective period, transmission dynamics, 
effective treatment and prevention methods including further test development, drug development and 
 vaccine  development which still remain unanswered. It is an attempt to briefly highlight the research 
gaps that still persist as limitations to the disease management strategies worldwide. In-depth and 
rigorous research is necessary to understand the puzzling epidemiological characteristics of COVID-19 
disease. Though we tried to analyse different epidemiological studies, there are certain limitations of 
information collection and availability. Nevertheless this study will hopefully help to identify 
epidemiological lacunae and aid a direction for the development of solid evidences. 
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